



Synthetic Biology Brings New Opportunity for Antibiotics Discovery

Guest Editors:

Dr. Yaojun Tong

State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China

Prof. Dr. Zixin Deng

State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

Prof. Dr. Linquan Bai

State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China

Deadline for manuscript submissions:

closed (10 September 2022)

Message from the Guest Editors

The limited availability of antibiotics, in addition to the rapid emergence of multidrug resistance, are putting us in a very dangerous position. Luckily, the advances of new technologies, especially biotechnologies, such as DNA sequencing, precise genome editing, system metabolic engineering, multiomics, synthetic biology, big data processing, and artificial intelligence are offering a great opportunity to develop better and efficient bioactive molecules, including next-generation antibiotics. Currently, various achievements and new discoveries from both academia and industry are taking place in the broad field of antibiotics, which reflects the fact that a new era is coming. As one of the most important driving forces, academia plays a critical role in drug discovery for a safer society, and thus, we would like to bring academia, industry, and clinic together in this Special Issue to report recent progress in antibiotics discovery.

Key words:

Antimicrobial; Antibiotics; Antivirus; Bioactive natural products; Multidrug resistance; Biosynthesis; Metabolic engineering; Synthetic biology; Advanced biotechnology; Microbial cell factory





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi